Display Settings:

Format

Send to:

Choose Destination

    Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2.

    Voriconazole therapeutic drug monitoring.

    Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D.

    University of Wisconsin, Department of Medicine, Madison, WI 53792, USA.

    We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P<0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 microg/ml, while disease progressed in 44% (n=18) of patients with concentrations below 2.05 microg/ml.

    PMID: 16569888 [PubMed - indexed for MEDLINE]

    PMCID: 1426935

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read Click here to read Click here to read

    Patient drug information

    • Voriconazole (Vfend®)

      Voriconazole is used to treat serious fungal infections such as invasive aspergillosis (a fungal infection that begins in the lungs and spreads through the bloodstream to other organs) and esophageal candidiasis (infecti...